<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35484785</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1523-5378</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Helicobacter</Title>
          <ISOAbbreviation>Helicobacter</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States.</ArticleTitle>
        <Pagination>
          <StartPage>e12894</StartPage>
          <MedlinePgn>e12894</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/hel.12894</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although endemic to much of the global population, few studies have examined Helicobacter pylori (H. pylori) in US refugee populations. This study investigates the prevalence of H. pylori infection and barriers to treatment in the International Family Medicine Clinic (IFMC), a primary care refugee clinic, in central Virginia.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted a chart review of 188 refugee patients of the IFMC who were referred for an H. pylori test between January 1, 2019, and December 31, 2020. Recorded measures included patient demographics, H. pylori test result, treatment of initial infection, completion of test of cure (TOC), TOC results, salvage therapy, and barriers to treatment. Binary logistic regression was performed to examine the association between demographic factors and H. pylori test results.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 171 patients who completed an H. pylori test, 94 tested positive (54.9%). Of the 93 patients that were subsequently treated, 76 were treated with clarithromycin triple therapy (82%). Forty-eight patients (52%) completed a TOC after completing treatment, and 21 (43%) of these patients remained positive, indicating persistent infection. Eighteen patients (90%) who remained positive for H. pylori were subsequently treated with quadruple therapy. Patients under 18 (OR = 0.25, p &lt; 0.01) and patients with a history of previous H. pylori (OR = 0.44, p &lt; 0.05) were less likely to have positive results on initial H. pylori testing. Common barriers to treatment included pregnancy, religious observance (e.g., fasting), and health system complications (e.g., prior authorization for medications, cost of treatment).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of H. pylori among refugees at the IFMC was higher than the overall prevalence estimate for the United States, which is consistent with previous studies. This work represents an updated picture of H. pylori prevalence among refugees in the United States and contributes to the identification of treatment barriers.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Helicobacter published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saif</LastName>
            <ForeName>Nadia</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-5024-0676</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Maryland School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jensen</LastName>
            <ForeName>Nicole</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farrar</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blackstone</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hauck</LastName>
            <ForeName>Fern R</ForeName>
            <Initials>FR</Initials>
            <Identifier Source="ORCID">0000-0001-7309-7665</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Helicobacter</MedlineTA>
        <NlmUniqueID>9605411</NlmUniqueID>
        <ISSNLinking>1083-4389</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>804826J2HU</RegistryNumber>
          <NameOfSubstance UI="D000658">Amoxicillin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H1250JIK0A</RegistryNumber>
          <NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000658" MajorTopicYN="N">Amoxicillin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017291" MajorTopicYN="N">Clarithromycin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005194" MajorTopicYN="N">Family Practice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016481" MajorTopicYN="Y">Helicobacter Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016480" MajorTopicYN="Y">Helicobacter pylori</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012036" MajorTopicYN="Y">Refugees</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antibiotic therapy</Keyword>
        <Keyword MajorTopicYN="N">epidemiology</Keyword>
        <Keyword MajorTopicYN="N">helicobacter pylori infection</Keyword>
        <Keyword MajorTopicYN="N">prevalence</Keyword>
        <Keyword MajorTopicYN="N">refugees</Keyword>
        <Keyword MajorTopicYN="N">treatment failure</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>0</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35484785</ArticleId>
        <ArticleId IdType="doi">10.1111/hel.12894</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Helicobacter pylori - Chapter 4-2020 Yellow Book | Travelers' Health | CDC. 2021. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/helicobacter-pylori</Citation>
        </Reference>
        <Reference>
          <Citation>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-238. doi:10.1038/ajg.2016.563</Citation>
        </Reference>
        <Reference>
          <Citation>Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420-429. doi:10.1053/j.gastro.2017.04.022</Citation>
        </Reference>
        <Reference>
          <Citation>Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014;59(8):1698-1709. doi:10.1007/s10620-014-3063-0</Citation>
        </Reference>
        <Reference>
          <Citation>Hamrah MH, Hamrah MS, Hamrah MH, et al. Prevalence of helicobacter pylori infection in dyspeptic patients in Andkhoy Afghanistan. Asian Pacific J Cancer Prev. 2017;18(11):3123-3127. doi:10.22034/APJCP.2017.18.11.3123</Citation>
        </Reference>
        <Reference>
          <Citation>U.S. Department of State. Bureau of Population, Refugees, and Migration RPC. Refugee Admissions Report as of September 30, 2021. Washington, DC. 2021. https://www.wrapsnet.org/admissions-and-arrivals/</Citation>
        </Reference>
        <Reference>
          <Citation>Korotkaya Y, Shores D. Helicobacter pylori in pediatric patients. Pediatr Rev. 2020;41(11):585-592. doi:10.1542/pir.2019-0048</Citation>
        </Reference>
        <Reference>
          <Citation>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991-1003. doi:10.1097/MPG.0000000000001594</Citation>
        </Reference>
        <Reference>
          <Citation>Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One. 2014;9(9):1-9. doi:10.1371/journal.pone.0108610</Citation>
        </Reference>
        <Reference>
          <Citation>McColl K. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597-1604.</Citation>
        </Reference>
        <Reference>
          <Citation>Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-876.</Citation>
        </Reference>
        <Reference>
          <Citation>Morais S, Costa AR, Ferro A, Lunet N, Peleteiro B. Contemporary migration patterns in the prevalence of helicobacter pylori infection: a systematic review. Helicobacter. 2017;22(3):1-11. doi:10.1111/hel.12372</Citation>
        </Reference>
        <Reference>
          <Citation>Abdul Rahim NR, Benson J, Grocke K, et al. Prevalence of helicobacter pylori infection in newly arrived refugees attending the migrant health service, South Australia. Helicobacter. 2017;22(2):1-5. doi:10.1111/hel.12360</Citation>
        </Reference>
        <Reference>
          <Citation>Cherian S, Forbes D, Sanfilippo F, Cook A, Burgner D. The epidemiology of helicobacter pylori infection in African refugee children resettled in Australia. Med J Aust. 2008;189:438-441. doi:10.5694/j.1326-5377.2008.tb02116.x</Citation>
        </Reference>
        <Reference>
          <Citation>Hulten KG, Lamberth LB, Kalfus IN, Graham DY. National and regional US antibiotic resistance to helicobacter pylori: lessons from a clinical trial. Gastroenterology. 2021;161(1):342-344.e1. doi:10.1053/j.gastro.2021.03.045</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
